Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JAB-23E73 in advanced solid tumors with KRAS alteration
NCT06973564Phase 2Recruiting
- Sponsor
- Jacobio Pharmaceuticals
- Start
- May 2025
- Primary completion
- Nov 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of JAB-23E73 in solid tumor, colorectal cancer (CRC), sponsored by Jacobio Pharmaceuticals. Started May 2025; status: recruiting.
02
Drugs
JAB-23E73
03
Conditions
solid tumorcolorectal cancer (CRC)
Beyond the preview
Go deeper on NCT06973564.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06973564.